Assessment	NNP
of	IN
the	DT
effect	NN
of	IN
potential	JJ
antifibrotic	JJ
compounds	NNS
on	IN
total	NN
and	CC
aVb6	NN
integrin-mediated	JJ
TGF-b	NN
activation	NN
.	.

Transforming-growth-factor-b	NN
(	(
TGF-b	NN
)	)
plays	VBZ
an	DT
important	JJ
role	NN
in	IN
the	DT
development	NN
of	IN
tissue	NN
fibrosis	NN
,	,
and	CC
molecules	NNS
inhibiting	VBG
this	DT
pathway	NN
are	VBP
attractive	JJ
therapeutic	JJ
targets	NNS
for	IN
fibrotic	JJ
diseases	NNS
such	JJ
as	IN
idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
.	.

Activation	NN
of	IN
TGF-b	NN
is	VBZ
the	DT
rate-limiting	JJ
step	NN
in	IN
TGF-b	NN
bioavailability	NN
,	,
and	CC
activation	NN
by	IN
the	DT
aVb6	NN
integrin	NN
is	VBZ
important	JJ
in	IN
fibrosis	NN
of	IN
the	DT
lung	NN
,	,
liver	NN
,	,
and	CC
kidney	NN
.	.

Activation	NN
of	IN
TGF-b	NN
by	IN
aVb6	NN
requires	VBZ
direct	JJ
cell-cell	JJ
contact	NN
and	CC
measurable	JJ
release	NN
of	IN
active	JJ
TGF-b	NN
in	IN
extracellular	JJ
fluid	NN
compartments	NNS
does	VBZ
not	RB
reflect	VB
tissue	NN
specific	JJ
activation	NN
.	.

The	DT
aim	NN
of	IN
this	DT
study	NN
was	VBD
to	TO
determine	VB
the	DT
effect	NN
of	IN
antifibrotic	JJ
compounds	NNS
on	IN
both	DT
total	JJ
,	,
and	CC
specific	JJ
aVb6	NN
integrin-mediated	JJ
TGF-b	NN
activity	NN
.	.

Using	VBG
a	DT
transformed	VBN
mink	NN
lung	NN
cell	NN
(	(
TMLC	NN
)	)
TGF-b	NN
reporter	NN
,	,
the	DT
effects	NNS
of	IN
potential	JJ
antifibrotic	JJ
therapies	NNS
including	VBG
an	DT
activin-like	JJ
kinase	NN
(	(
Alk5	NN
)	)
inhibitor	NN
,	,
Dexamethasone	NN
,	,
Pirfenidone	NN
,	,
N-acetylcysteine	NN
(	(
NAC	NN
)	)
,	,
and	CC
BIBF1120	NN
were	VBD
assessed	VBN
.	.

Effects	NNS
due	JJ
to	TO
aVb6	NN
integrin-mediated	JJ
TGF-b	NN
activity	NN
were	VBD
measured	VBN
using	VBG
reporter	NN
cells	NNS
cocultured	VBN
with	IN
cells	NNS
expressing	VBG
aVb6	NN
integrins	NNS
.	.

These	DT
high-throughput	JJ
studies	NNS
were	VBD
validated	VBN
using	VBG
a	DT
phosphorylated	VBN
Smad2	NN
Enzyme-Linked	NNP
Immunosorbent	NNP
Assay	NN
.	.

Alk5	NN
inhibitors	NNS
are	VBP
potent	JJ
inhibitors	NNS
of	IN
TGF-b	NN
activity	NN
,	,
whereas	IN
the	DT
novel	JJ
antifibrotics	NNS
,	,
Pirfenidone	NN
,	,
BIBF1120	NN
,	,
and	CC
NAC	NN
are	VBP
only	RB
moderate	JJ
inhibitors	NNS
,	,
and	CC
Dexamethasone	NN
does	VBZ
not	RB
specifically	RB
affect	VB
TGF-bactivity	NN
,	,
but	CC
inhibits	VBZ
TGF-b-induced	JJ
gene	NN
expression	NN
.	.

None	NN
of	IN
the	DT
current	JJ
small	JJ
molecular	JJ
inhibitors	NNS
inhibit	VBP
aVb6-mediated	JJ
TGF-b	NN
activity	NN
.	.

These	DT
results	NNS
demonstrate	VBP
the	DT
potential	NN
of	IN
this	DT
high-throughput	JJ
assay	NN
of	IN
aVb6-specific	JJ
TGF-b	NN
activity	NN
and	CC
illustrate	VBP
that	IN
currently	RB
available	JJ
antifibrotics	NNS
have	VBP
limited	VBN
effects	NNS
on	IN
aVb6	NN
integrin-mediated	JJ
TGF-b	NN
activity	NN
.	.

